Core Viewpoint - Meinuo Pharma has received approval from the National Medical Products Administration for the registration of Irbesartan Hydrochlorothiazide tablets, enhancing its market competitiveness and expanding its cardiovascular product pipeline [1] Group 1 - Meinuo Pharma's wholly-owned subsidiary, Ningbo Meinuo TianKang Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Irbesartan Hydrochlorothiazide tablets [1] - The drug is indicated for the treatment of primary hypertension, which addresses a significant health issue [1] - The approval allows the company to produce and sell the drug in the domestic market, positively impacting its operational development [1]

Core Viewpoint - Zhejiang Anglikang Pharmaceutical Co., Ltd. has received the drug registration certificate for Levofloxacin Tablets from the National Medical Products Administration, which is expected to enhance the company's product pipeline and market presence [1][2]. Group 1: Drug Information - Levofloxacin Tablets are the left-handed optical isomer of Ofloxacin, classified as a third-generation fluoroquinolone antibiotic, known for its broad antibacterial spectrum and strong antibacterial action [1]. - The drug is indicated for the treatment of moderate to severe infections in adults (≥18 years) caused by specified sensitive strains, including hospital-acquired pneumonia, community-acquired pneumonia, acute bacterial sinusitis, acute exacerbations of chronic bronchitis, complex skin and skin structure infections, uncomplicated skin and soft tissue infections, and chronic bacterial prostatitis [1]. Group 2: Impact on the Company - The approval of Levofloxacin Tablets will further enrich the company's product pipeline, potentially leading to increased market opportunities [2]. - However, the sales of pharmaceuticals are subject to uncertainties due to the unique nature of the industry, influenced by national policies and market environment changes [2].

Group 1 - Warner Pharmaceuticals received the drug registration certificate for polyethylene glycol sodium potassium powder, which is indicated for the treatment of chronic constipation and fecal impaction [1] - The approval of the drug registration certificate enriches the company's formulation product variety and positively impacts the optimization of the product structure [1] - Warner Pharmaceuticals reported a revenue of 714 million yuan for the first half of 2025, a year-on-year decrease of 3.37%, with a net profit attributable to shareholders of 71 million yuan, down 36.95% [1] Group 2 - Renfu Pharmaceutical announced that its subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., received the drug registration certificate for dapoxetine hydrochloride tablets, which are used to treat premature ejaculation [2] - The total sales of dapoxetine hydrochloride tablets in 2024 are estimated to be around 1.1 billion yuan, with major manufacturers including Shandong Huabo Kaisheng Biotechnology Co. and Sichuan Kelun Pharmaceutical Co. [2] - Anglikon received the drug registration certificate for azilsartan potassium tablets, which are indicated for the treatment of primary hypertension in adults [3] - Xinhua Pharmaceutical announced the approval of fumarate bisoprolol tablets, indicated for hypertension and chronic stable heart failure with reduced left ventricular function [3]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Huaren Shuanghe Limin Pharmaceutical (Jinan) Co., Ltd., has received a drug registration certificate for Bosentan dispersible tablets from the National Medical Products Administration (NMPA) [1][2]. Group 1: Drug Registration and Development - The drug Bosentan dispersible tablets are indicated for pulmonary arterial hypertension (PAH) in pediatric patients aged 3 years and older, as well as for adult patients classified as WHO functional class II to IV [1][2]. - The development of this generic drug began in 2022, with the application for marketing authorization submitted on June 14, 2024, and approval granted on September 23, 2025 [2]. Group 2: Market Situation - Bosentan dispersible tablets were developed by Actelion Pharmaceuticals Ltd and were approved for sale in the EU in 2009 under the brand name "Tracleer." The drug was imported into China in September 2019 under the brand name "Quankeli" [3]. - In 2024, the global sales of Bosentan dispersible tablets reached approximately $35.9 million, with "Tracleer" accounting for about $31.3 million of that total [3]. - In the Chinese market, the total sales of Bosentan dispersible tablets were approximately 2.126 million yuan in 2024, with Johnson & Johnson holding a 100% market share [3]. Group 3: Impact on the Company - The acquisition of the drug registration certificate is expected to enhance the company's product line and market competitiveness, while also providing valuable experience for future product development [4].

Core Viewpoint - Aimer (300896.SZ) announced that its wholly-owned subsidiary, Beijing Nobot Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for the registration of Minoxidil topical solution in 2% and 5% concentrations, which are non-prescription dermatological medications [1] Group 1 - The 2% formulation is indicated for the treatment of androgenetic alopecia and alopecia areata [1] - The 5% formulation is restricted for use by males only, also for the treatment of androgenetic alopecia and alopecia areata [1] - Minoxidil is a peripheral vasodilator that, when used topically over a long period, can stimulate hair growth in male patients suffering from androgenetic alopecia and alopecia areata [1]

Core Viewpoint - Aimeike (300896.SZ) announced that its wholly-owned subsidiary, Beijing Nobot Biotechnology Co., Ltd., received the drug registration certificate for Minoxidil topical solution from the National Medical Products Administration [1] Group 1: Product Details - The Minoxidil topical solution is available in two specifications: 2% and 5% [1] - The 2% specification is indicated for the treatment of androgenetic alopecia and alopecia areata [1] - The 5% specification is restricted for use in males only, specifically for treating androgenetic alopecia and alopecia areata [1]

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has received the drug registration certificate for Carbetocin Injection from the National Medical Products Administration, which is expected to enhance the company's product line and market competitiveness [1][4]. Drug Basic Information - Drug Name: Carbetocin Injection - Dosage Form: Injection - Specification: 5ml: 25mg (calculated as C??H??N?NaO?S·3H?O) - Registration Category: Class 3 Chemical Drug - Approval Number: National Drug Approval Number H20255532 - The drug is approved for domestic production [1][2]. Market Potential - Carbetocin Injection is used for treating bleeding diseases in the urinary system, upper digestive tract, respiratory tract, and gynecology, with significant efficacy in the urinary system. It can also be used for the prevention and treatment of surgical bleeding [2]. - The domestic market sales forecast for Carbetocin Injection in 2024 is approximately RMB 250 million [2]. R&D Investment - The company has invested approximately RMB 7.12 million in the R&D project for Carbetocin Injection [3]. Impact on the Company - The approval of Carbetocin Injection as a Class 3 Chemical Drug is equivalent to passing the consistency evaluation, which enriches the company's product line and positively impacts its operational development [4].

Core Viewpoint - Hendi Pharmaceutical has obtained the drug registration certificate for Ibuprofen suspension from the National Medical Products Administration as of June 2025, and is currently preparing for product launch and sales [1] Company Developments - The company is actively working on the preliminary preparations for the product's market launch following the receipt of the registration certificate [1] - The impact of the product registration on the company's operating performance is not expected to be significant in the short term [1] Market Considerations - Future revenue generation from the product is uncertain due to factors such as non-uniqueness of the product, competition from similar products, and the effectiveness of the company's business promotion and sales scale [1]

Core Viewpoint - The company has received the drug registration certificate for Famotidine injection from the National Medical Products Administration, which enhances its product line and market competitiveness [1] Summary by Relevant Sections - **Product Approval** - The company has obtained the drug registration certificate for Famotidine injection, a medication that works by inhibiting gastric acid secretion and belongs to the H2 receptor antagonist class [1] - **Impact on Product Line** - The approval of Famotidine injection enriches the company's product offerings, contributing to improved market competitiveness [1] - **Financial Impact** - The acquisition of the drug registration certificate is not expected to have a significant impact on the company's recent operating performance [1]

Group 1 - The company Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd., received a drug registration certificate from the National Medical Products Administration for "Sulfate Terbutaline Nebulization Solution" [1] - The indication for the sulfate terbutaline nebulization solution is to relieve bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [1]